In this article, we will list the 5 Best Medical Technology Stocks to Buy Right Now. Please visit 11 Best Medical Technology Stocks to Buy Right Now if you would like to see the extended list and the methodology behind it.
5. Abbott Laboratories (NYSE:ABT)
Number of Hedge Fund Holders: 71
Stock Upside: 30.12%
Abbott Laboratories (NYSE:ABT) is one of the best medical technology stocks to buy right now. On April 28, Abbott Laboratories (NYSE:ABT) announced that the US Food and Drug Administration (FDA) and European regulators granted clearance and CE Mark approval, respectively, for its next-generation Ultreon 3.0 software. The software is an AI-powered coronary imaging platform designed to assist cardiologists in treating blocked heart arteries.
Abbott said that Ultreon 3.0 is the first optical coherence tomography (OCT) system in both the US and Europe that combines high-resolution images of coronary artery plaque with AI-automated analysis in a single, integrated workflow. OCT works by using infrared light to capture detailed cross-sectional images of the inside of an artery, and the system achieves a full pullback scan in just one second.
The challenge the platform seeks to address is to enable doctors to place stents properly to restore blood flow in a blocked artery. Ultreon 3.0 addresses this challenge by using AI to analyze OCT images in real time and giving the physician a faster, more precise decision-making tool during the procedure.
The platform also offers an advantage over intravascular ultrasound, or IVUS, said Abbott. IVUS is a competing imaging approach. It added that unlike IVUS, Ultreon 3.0 delivers higher-resolution images while requiring little to no contrast dye. This way, it reduces the risk of contrast-induced kidney complications in some patients.
Abbott Laboratories (NYSE:ABT) is a diversified medical technology and healthcare company. It develops diagnostics, medical devices, nutrition products, and branded generic pharmaceuticals.
4. Stryker Corporation (NYSE:SYK)
Number of Hedge Fund Holders: 67
Stock Upside: 21.15%
Stryker Corporation (NYSE:SYK) is one of the best medical technology stocks to buy right now. On May 12, Argus analyst David Toung cut his price target on Stryker Corporation (NYSE:SYK) to $350 from $435 while keeping a Buy rating. This call followed a cyberattack that upended Stryker’s first quarter and sent its stock to a 52-week low.
Stryker suffered the cyberattack on March 11, which disrupted the company’s global information technology network. It resulted in client devices and servers becoming dysfunctional, and portions of the company’s operations ground to a halt.
Be that as it may, Stryker’s Q1 2026 results were robust; revenue grew 2.6% year over year to touch $6.02 billion, though it was lower than the $6.35 billion analysts expected. The EPS also came in lower at $2.60 against the expected $2.98, an 8.5% year over year decline.
The misses, however, did not dampen management’s optimism because they stuck with their full-year 2026 guidance. To Argus’s Toung, this was an important signal of the company’s resilience. He noted that Stryker’s strong underlying business execution and solid customer demand remained intact even as the near-term financial picture was distorted by the attack.
However, the analyst pointed out that the cyberattack damaged Stryker’s chances of achieving double-digit top-line revenue growth in 2026. His view was that Stryker could have easily managed that level of growth but the reputational and operational damage from the incident is just too much to ignore.
Stryker Corporation (NYSE:SYK) is a medical technology company that develops and manufactures products for orthopedics, medical and surgical equipment, and neurotechnology. Its portfolio includes joint replacement implants, trauma and spine devices, surgical navigation and robotic-assisted systems such as Mako.
3. Intuitive Surgical, Inc. (NASDAQ:ISRG)
Number of Hedge Fund Holders: 109
Stock Upside: 29.17%
Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the best medical technology stocks to buy right now. On May 21, Intuitive Surgical, Inc. (NASDAQ:ISRG) announced a major round of updates to its da Vinci 5 robotic surgical system, including extended instrument use capabilities. The company said more than 100 improvements will roll out to US customers starting June this year, and that global availability will depend on regulatory clearances in each market.
The da Vinci 5 is Intuitive’s most advanced robotic surgery platform. It features over 150 design innovations, 10,000 times the computing power of its predecessor, the da Vinci Xi, and Force Feedback technology. The latter is a first-of-its-kind feature that lets surgeons physically sense the pressure their instruments exert on tissue during a procedure, which the company said reduces tissue force by up to 43% in preclinical trials.
A key part of this update is that five of the six available Force Feedback instruments will now last 15 uses per instrument. They could only last six uses previously. Intuitive said this is a massive improvement because more uses per instrument lowers the per-procedure cost of running the system.
The company is also enhancing the Intuitive Telepresence feature, which allows surgeons at a remote location to observe and guide a live procedure. It will get a new camera that provides a full panoramic view of the operating room and a live cursor tool. The improvement will give the remote physician a clearer picture of the surgical environment.
Intuitive Surgical, Inc. (NASDAQ:ISRG) is a medical technology company that designs and manufactures robotic-assisted surgical systems. The most notable is the da Vinci surgical platform used in minimally invasive procedures across specialties such as urology, gynecology, and general surgery.
2. Boston Scientific Corporation (NYSE:BSX)
Number of Hedge Fund Holders: 110
Stock Upside: 49.11%
Boston Scientific Corporation (NYSE:BSX) is one of the best medical technology stocks to buy right now. On May 19, TD Cowen reiterated its Buy rating and $80 price target on Boston Scientific Corporation (NYSE:BSX).
TD Cowen constructed its thesis around Boston Scientific’s Fracture IDE study. The study tested the company’s SEISMIQ 4CE Coronary Intravascular Lithotripsy (IVL) Catheter, which is designed to treat severely calcified coronary artery disease (CAD). It uses laser energy inside a balloon catheter to generate acoustic pressure waves that fracture calcium deposits, preparing the vessel for stent implantation
The IDE trial was about testing the device to see if it solves the problem of a poorly expanded stent when removing built up hard calcium deposits in arteries. Boston Scientific said in a press release that the trial proved the safety of the SEISMIQ 4CE. Also, the procedure was a success in over 93% of patients, which means the company proved the device’s effectiveness.
TD Cowen had anticipated positive results from the IDE trial. Particularly, the firm characterized the coronary IVL market as offering double-digit growth and projected it will become a $1.5 billion market in the near term. The firm noted that Boston Scientific’s SEISMIQ 4CE device targets a first-half 2027 US launch if the regulatory process proceeds as planned.
Boston Scientific Corporation (NYSE:BSX) is a medical technology company that develops and manufactures minimally invasive medical devices used in interventional cardiology, electrophysiology, endoscopy, urology, and neuromodulation. Its product portfolio includes coronary stents, cardiac rhythm management devices, ablation systems for treating heart arrhythmias, and advanced endoscopy tools used in diagnostic and therapeutic procedures.
1. Thermo Fisher Scientific Inc. (NYSE:TMO)
Number of Hedge Fund Holders: 113
Stock Upside: 36.68%
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the best medical technology stocks to buy right now. On May 20, Thermo Fisher Scientific Inc. (NYSE:TMO) hosted its annual Investor Day in New York City, where CEO Marc N. Casper and the senior leadership team outlined the company’s long-term financial targets and strategic priorities.
A key highlight of the event was the company’s leadership targeting a 7% organic revenue CAGR over the long term. Put simply, the executives expect the company to grow its underlying business at that pace annually, excluding acquisitions and currency swings.
For context, Thermo Fisher posted a 1% organic revenue growth in Q1 2026, its most recent quarter. Total revenue grew 6% to $11.01 billion, largely on the back of acquisitions and favorable currency. As such, the 7% organic target is a massive ambition.
The company also used Investor Day to reinforce its position as the dominant end-to-end partner for life sciences customers. Management argued that the company’s breadth and scale make it uniquely difficult for customers to replace.
On the same day, Thermo Fisher’s Board of Directors declared a quarterly cash dividend of $0.47 per common share. The payment will be disbursed later this year, on July 15, to shareholders of record as of June 15.
Thermo Fisher Scientific Inc. (NYSE:TMO) is a medical technology and life sciences company. It provides analytical instruments, laboratory equipment, diagnostics, and biotechnology services to healthcare providers, pharmaceutical companies, and research institutions worldwide.
While we acknowledge the potential of TMO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TMO and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 7 Best Augmented Reality Penny Stocks to Buy and 10 Best Gene Therapy Stocks to Buy in 2026.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
